[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"National Cancer Center, Korea\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":603},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,23,0,[8,43,74,111,141,165,188,216,240,263,289,312,336,359,383,405,432,457,487,510,531,556,581],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100053561","prospective-study-of-ultrahypofractionated-proton-beam-therapy-for-localized-prostate-cancer-100053561",false,"NCT07699705","Prospective Study of Ultrahypofractionated Proton Beam Therapy for Localized Prostate Cancer","Prospective Cohort Study for Identifying Factors Predicting Long-term Outcomes of Prostate Cancer Patients Who Received Ultrahypofractionated Proton Beam Therapy","Inclusion Criteria:\n\n* Histologically confirmed localized adenocarcinoma of the prostate.\n* No evidence of distant metastasis (M0).\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.\n* Eligible to receive definitive image-guided ultrahypofractionated pencil beam scanning proton beam therapy according to the study protocol.\n* Ability to complete study questionnaires and comply with scheduled follow-up assessments.\n* Provision of written informed consent before study enrollment.\n\nExclusion Criteria:\n\n* Residual or recurrent prostate cancer following prior radical prostatectomy.\n* Previous pelvic radiotherapy.\n* Evidence of distant metastatic disease.\n* Active malignancy within the previous 1 year, except adequately treated basal cell carcinoma or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, or completely resected T1N0M0 malignancies.\n* Uncontrolled psychiatric illness, severe traumatic brain injury, chronic alcohol or substance dependence, or other medical conditions that, in the investigator's judgment, would preclude safe participation or adequate follow-up.\n* Inability or unwillingness to provide written informed consent or comply with study procedures.","MALE","19 Years",{"count":19,"type":20},50,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this prospective observational cohort study is to evaluate the long-term efficacy and safety of ultrahypofractionated proton beam therapy in patients with localized prostate cancer and to identify clinical and treatment-related factors associated with oncologic outcomes and treatment-related toxicity.\n\nThe main questions it aims to answer are:\n\nWhat are the long-term biochemical recurrence-free survival, clinical progression-free survival, overall survival, and acute and late treatment-related toxicity outcomes following ultrahypofractionated proton beam therapy? Which clinical characteristics, treatment planning parameters, and patient-reported outcomes are predictive of long-term oncologic outcomes and treatment-related toxicity?\n\nParticipants will:\n\nReceive protocol-based ultrahypofractionated proton beam therapy (35-40 Gy\\[RBE\\] in 5 fractions).\n\nUndergo routine clinical evaluation, laboratory testing including prostate-specific antigen (PSA), and imaging studies according to the institutional follow-up schedule.\n\nComplete patient-reported outcome questionnaires (EPIC-CP and Visual Analog Scale \\[VAS\\]) before treatment and during follow-up.\n\nBe followed prospectively to assess biochemical recurrence, clinical progression, survival outcomes, and acute and late treatment-related toxicities.",[26],"Prostate Neoplasm",[28,29],"prostate neoplasm","proton therapy","RECRUITING","2026-07-09",{"date":33,"type":34},"2026-07-13","ACTUAL",{"date":36,"type":34},"2024-11-04",{"date":38,"type":20},"2034-12-31",{"name":40,"class":41},"National Cancer Center, Korea","OTHER_GOV",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":51,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":42},"100545960","phase-2-the-clinical-effectiveness-and-safety-of-intravesical-mitomycin-c-and-gemcitabine-sequential-therapy-100545960","NCT06388720","The Clinical Effectiveness and Safety of Intravesical Mitomycin-C and Gemcitabine Sequential Therapy","A Study to Assess the Clinical Effectiveness and Safety of Intravesical Mitomycin-C and Gemcitabine Sequential Therapy in Patients With High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to BCG Therapy","IMGeS","Inclusion Criteria:\n\n1. a patient over the age of 20\n2. Patients who are willing and able to complete a written test subject consent\u002Fapproval for this examination.\n3. Histologically confirmed high-risk NMIBC (according to AUA guidelines; High-grade T1 disease, any recurrent high-grade Ta, high-grade Ta \\>3 cm, high-grade Ta that is multifocal, any carcinoma in situ, any BCG failure in high-grade patients, any variant histology, any lymphovascular invasion, and any high-grade prostatic urethral involvement) with prior BCG therapy.\n4. The most recent bladder examination\u002FTURBT must be performed within 8 weeks before the initial administration of the trial treatment. Patients with high risk NMIBC who received proper BCG treatment but did not respond to BCG\n5. Patients who are not eligible for a radical bladder resection or who have refused surgery.\n6. Patient who are not being pregnant or breast feeding until the study period.\n\nExclusion Criteria:\n\n1. Patient diagnosed with muscle-invasive bladder cancer at TURBT\n2. If upper urinary tract urothelial cancer is accompanied by imaging\n3. If the imaging indicates extravesical involvement (cT3)\n4. Imaging shows lymph node metastasis (short-axis 15mm or more) or distant metastasis\n5. In a biopsy, non-transitional cell histology is dominant, or only non-transitional cell tissue is present (primary squamous cell carcinoma, primary adenocarcinoma, small cell carcinoma, sarcoma, carcinosarcoma, paraganglioma, melanoma, lymphoma)\n6. In the case of receiving systemic cytotoxic chemotherapy for other cancers within 3 years\n7. If patient have a history of pelvic radiation therapy for other cancers within 3 years\n8. If patient have a history of receiving Mitomycin-c or gemcitabine in the bladder within 3 years. The exception is cases used for the purpose of injection therapy of anticancer drugs in the early bladder cancer\n9. If patient has a history of allergy to mitomycin-c or gemcitabine\n10. Cystoscopy shows a tumor in the prostate urethra\n11. Patients who have participated in studies using clinical trial drugs and are currently receiving clinical trial drugs or who have used clinical trial drugs or clinical trial medical devices within 4 weeks prior to the date of initial treatment\n12. After post-cystoscopy\u002FTURBT, the patient received intravesical chemotherapy prior to the start of trial treatment\n13. Thrombocytopenia, coagulopathy or bleeding tendency patient.\n14. Pregnant or breast-feeding women\n15. If patient treated yellow fever vaccine or phenytoin\n16. Dysfunction of liver or kidney (GFP≤30)\n17. If patient undergo severe myelosuppression\n18. If patient complicated severe infection\n19. If patient definitely diagnosed interstitial lung disease or lung fibrosis by chest X-ray.\n20. If patient conduct chest radiotherapy.","ALL","20 Years",{"count":54,"type":20},82,[56],"PHASE2","The aim of this study is to evaluate the effectiveness and safety of mitomycin-c and gemcitabine sequential instillation in BCG unresponsive high risk non-muscle invasive bladder cancer patients.",[59],"Bladder Cancer",[61,62,63,64,65],"high risks non-muscle invasive bladder cancer","Sequential treatment","Intravesical treatment","Mitomycin-c","Gemcitanine","2026-05-27",{"date":68,"type":34},"2026-05-29",{"date":70,"type":34},"2024-11-19",{"date":72,"type":20},"2028-12-31",{"name":40,"class":41},{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":51,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":21,"phases":86,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},"100502843","phase-3-interval-cytoreductive-surgery-with-or-without-hipec-for-ovarian-cancer-focus--kov-hipec-04-100502843","NCT05827523","Interval Cytoreductive Surgery With or Without HIPEC for Ovarian Cancer (FOCUS \u002F KOV-HIPEC-04)","Phase III Randomized Trial of HIPEC in Primary Stage Three & Four Primary Ovarian Cancer After Interval Cytoreductive Surgery (FOCUS, KOV-04)","FOCUS \u002F KOV-04","Inclusion Criteria:\n\n1. Signed and written informed consent,\n2. Patients ≥18, \\\u003C80 years old,\n3. Diagnosed with histologically confirmed FIGO stage III-IV primary epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer treated with three cycles of neoadjuvant chemotherapy,\n4. Treated with interval complete cytoreduction, or cytoreduction with no more than 2.5 mm depth of residual disease,\n5. A life expectancy \\> 3 months as clinically judged,\n6. Adequate organ function for cytoreductive surgery and HIPEC,\n7. Women who are medically unable to conceive or who are of childbearing potential, agree to follow contraceptive guidelines during treatment and,\n8. Patients can also consent to the provision of clinical information for secondary use, such as future biomedical research. However, in the future, subjects can participate in the main trial even if they do not intend to participate in sharing clinical information.\n\nExclusion Criteria:\n\n1. Diagnosed with non-epithelial ovarian carcinoma or borderline ovarian tumor\n2. Patients who have not undergone neoadjuvant chemotherapy,\n3. Interval cytoreduction with more than 2.5 mm depth of residual disease,\n4. A life expectancy ≤3 months as clinically judged,\n5. History of previous malignancy within five years prior to inclusion, that affects ovarian cancer treatment results, with the exception of carcinoma in situ, radically excised basal cell or squamous cell cancer of the skin, or synchronal endometrial carcinoma FIGO IA G1\u002F2,\n6. Patients with myelodysplastic syndrome (MDS)\u002Facute myeloid leukemia (AML) or with features suggestive of MDS\u002FAML,\n7. Patients with active central nervous system metastasis and carcinoma meningitis or patients who have been previously treated for brain metastases must be in a stable state in radiology,\n8. Patients with antibacterial, antifungal, or antiviral infections requiring systemic treatment (administration of parenteral antibiotics),\n9. Active tuberculosis that is not controlled within 1 month of treatment,\n10. Patients diagnosed with a psychiatric disorder or substance abuse disorder that would interfere with your ability to cooperate with the trial,\n11. Patients with any contraindications to the use of cisplatin (i.e., hypersensitivity to cisplatin),\n12. Patients with a history of allogeneic tissue\u002Fsolid organ transplantation or bone marrow transplantation or a history of double umbilical cord transplantation or,\n13. History or current evidence of any condition, therapy, or laboratory abnormality that may confound the results of the study, or interfere with the patient's participation, in the opinion of the treating investigator.","18 Years","80 Years",{"count":85,"type":20},520,[87],"PHASE3","Primary stage III-IV epithelial ovarian cancer randomizing between interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC)",[90],"Ovarian Cancer",[92,93,94,95,96,97,98,99,100,101],"Ovarian cancer","Hyperthermic intraperitoneal chemotherapy","HIPEC","Interval cytoreductive surgery","Neoadjuvant chemotherapy","Carcinoma, Ovarian Epithelial","Epithelial ovarian cancer","FOCUS","kov-hipec-04","kov-04","2026-02-11",{"date":104,"type":34},"2026-02-13",{"date":106,"type":34},"2023-05-31",{"date":108,"type":20},"2030-12-31",{"name":40,"class":41},10,{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":51,"minAge":17,"maxAge":119,"enrollmentInfo":120,"targetDuration":4,"studyType":21,"phases":122,"briefSummary":123,"conditions":124,"keywords":128,"overallStatus":132,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":42},"100623663","effect-of-exercise-on-chemotherapy-induced-peripheral-neuropathy-100623663","NCT07399561","Effect of Exercise on Chemotherapy-Induced Peripheral Neuropathy","A Randomized Controlled Trial Evaluating the Effects of Exercise on Chemotherapy-Induced Peripheral Neuropathy in Patients Treated With Oxaliplatin or Paclitaxel","EX-CIPN","Inclusion Criteria:\n\n* Diagnosis of colorectal cancer (oxaliplatin cohort) or gynecologic cancer (paclitaxel cohort)\n* Planned initiation of oxaliplatin- or paclitaxel-based chemotherapy\n* Karnofsky Performance Status ≥70\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Pre-existing peripheral neuropathy from other causes\n* Severe comorbidities limiting safe participation in exercise\n* Regular participation in a structured moderate- to high-intensity exercise program comparable to the study intervention prior to enrollment.\n* Cognitive impairment interfering with study participation","75 Years",{"count":121,"type":20},140,[23],"Chemotherapy-induced peripheral neuropathy (CIPN) is a common and often persistent adverse effect of oxaliplatin- and paclitaxel-based chemotherapy. While exercise is frequently recommended for patients with CIPN, it remains unclear whether exercise mitigates neuropathic injury itself or primarily improves physical function and quality of life.\n\nThis randomized controlled trial evaluates the effects of exercise on CIPN during and after chemotherapy. Patients receiving oxaliplatin for colorectal cancer or paclitaxel for gynecologic cancer are randomized to an exercise intervention or usual-care control. Neuropathy severity is assessed using objective neurophysiological measures, blood biomarkers, and validated clinical and patient-reported outcomes.",[125,126,127],"Peripheral Neuropathy, Secondary to Drugs or Chemicals","Oxaliplatin Induced Peripheral Neuropathy in Cancer Patients","Paclitaxel Induced Neuropathy",[129,130,131],"chemotherapy induced peripheral neuropathy","CIPN","Exercise","NOT_YET_RECRUITING","2026-02-02",{"date":135,"type":34},"2026-02-10",{"date":137,"type":20},"2026-02-03",{"date":139,"type":20},"2027-12-31",{"name":40,"class":41},{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":51,"minAge":17,"maxAge":4,"enrollmentInfo":149,"targetDuration":4,"studyType":21,"phases":150,"briefSummary":151,"conditions":152,"keywords":154,"overallStatus":132,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":4},"100615826","phase-2-first-line-lenvatinib-in-child-pugh-b-patients-with-hcc-unsuitable-for-curative-treatment-100615826","NCT07297654","First-Line Lenvatinib in Child-Pugh B Patients With HCC Unsuitable for Curative Treatment","First-Line Lenvatinib in Child-Pugh B Patients With HCC Unsuitable for Curative Treatment: A Phase 2 FINELAND Trial","FINELAND","Inclusion Criteria:\n\n1. Signed informed consent\n2. Age ≥ 19 years at the time of signing informed consent\n3. Histological or clinical diagnosis of HCC according to the Korean Liver Cancer Association-National Cancer Center guidelines\n4. HCC not amenable to curative treatment (e.g., surgical resection, local therapy, liver transplantation)\n5. At least one measurable target lesion according to RECIST v1.1\n\n   \\- Participants who previously received local treatment (e.g., radiofrequency ablation, microwave ablation, transarterial chemoembolization, transarterial radioembolization, transarterial embolization, or radiotherapy) are eligible if (a) target lesions have not been treated by prior local therapy, or (b) lesions within the field of local therapy have subsequently progressed according to RECIST v1.1.\n6. Child-Pugh class B7-B8\n7. ECOG performance status (PS) 0-2\n8. Adequate hematologic and end-organ function defined by the following laboratory tests obtained within 14 days prior to screening:\n\n   * Hemoglobin ≥ 8.0g\u002FdL\n   * Absolute neutrophil count (ANC) ≥ 1,000\u002Fmm3\n   * Platelet count ≥ 50,000\u002FμL\n   * Total bilirubin \\\u003C 3.5 mg\u002FdL\n   * Serum albumin ≥ 2.5 g\u002FdL\n   * ALT and AST ≤ 7 x upper limit of normal (ULN)\n   * Prothrombin time (INR ≤ 1.8 × ULN)\n   * Serum creatinine ≤ 2.0 × ULN or calculated creatinine clearance ≥ 40 mL\u002Fmin (Cockcroft-Gault equation)\n9. Documented virological status for hepatitis B virus (HBV) and hepatitis C virus (HCV) by screening tests.\n\n   \\- Participants with HBV or HCV infection must receive antiviral therapy in accordance with institutional guidelines.\n10. Women of childbearing potential must agree to remain abstinent or use effective contraception (failure rate \\\u003C 1% per year) from signing informed consent through at least 6 months after the last study drug administration.\n\nMen must agree to remain abstinent or use effective contraception (failure rate \\\u003C 1% per year) during the same period and refrain from sperm donation.\n\nExclusion Criteria:\n\n1. Fibrolamellar carcinoma or sarcomatoid carcinoma\n2. Prior systemic therapy for HCC\n3. Local therapy for HCC (including radiofrequency ablation, microwave ablation, cryoablation, transarterial chemoembolization, radioembolization, or radiotherapy) within 28 days prior to initiation of study treatment, or unresolved complications from such procedures\n\n   \\- Palliative radiotherapy to bone lesions is permitted with a 7-day washout\n4. History of allogeneic stem cell or solid organ transplantation\n5. Active brain metastases or leptomeningeal disease\n6. History of another malignancy within 2 years prior to screening, except for cancers with negligible risk of metastasis or death (e.g., \\>90% 5-year survival)\n7. Serious uncontrolled medical comorbidities within 3 months prior to study treatment, including severe cardiovascular disease (NYHA class ≥ II heart disease, myocardial infarction, or cerebrovascular accident), unstable arrhythmia, or unstable angina, or any condition judged by the investigator to increase participant risk\n8. Pregnant or breastfeeding women, or men and women of reproductive potential unwilling to use effective contraception from screening through 6 months after the last study drug administration\n9. Any condition judged by the investigator to interfere with compliance with study procedures, restrictions, or requirements",{"count":19,"type":20},[56],"This study aims to evaluate the efficacy and safety of lenvatinib as first-line therapy in patients with Child-Pugh class B HCC who are unsuitable for curative treatment.",[153],"Advanced Hepatocellular Carcinoma",[155,156],"Lenvatinib","child Pugh B","2026-01-05",{"date":159,"type":34},"2026-01-07",{"date":161,"type":20},"2026-02",{"date":163,"type":20},"2028-05",{"name":40,"class":41},{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":171,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":51,"minAge":17,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":21,"phases":175,"briefSummary":176,"conditions":177,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":187},"100579752","phase-2-a-study-comparing-immunotherapy-alone-versus-immunotherapy-combined-with-radiotherapy-in-patients-with-hepatocellular-carcinoma-hcc-with-vascular-invasion-100579752","NCT06828380","A Study Comparing Immunotherapy Alone Versus Immunotherapy Combined With Radiotherapy in Patients With Hepatocellular Carcinoma (HCC) With Vascular Invasion","A Phase II Study of Immunotherapy With or Without Particle Beam Radiation Therapy in Patients With Advanced Hepatocellular Carcinoma Who Have Vascular Invasion: IOPT Study","IOPT","Inclusion Criteria:\n\n1. Signed informed consent form\n2. Age \\>= 19 at the time of signing Informed consent form\n3. Histological or clinical diagnosis of HCC based on the guidelines of the Korean Liver Cancer Association -National Cancer Center\n4. Unresectable and\u002For locally advanced or metastatic disease showing major vascular invasion\n\n   a. Presence of major vascular invasion on dynamic CT or dynamic MRI (1+2)\n   * an intraluminal filling defect adjacent to the primary tumor in portal vein, hepatic vein, and\u002For inferior vena cava\n   * an enhancement of the filling defect on arterial phase and a washout on portal\u002Fdelayed phases\n5. Having at least one measurable target lesion (per RECIST v1.1)\n\n   a. Participants who received prior locoregional therapy (e.g., radiofrequency ablation, microwave ablation, transarterial chemoembolization, transarterial radioembolization, transarterial embolization, radiation therapy etc.) are eligible provided that other target lesion(s) have not been previously treated with locoregional therapy or the target lesion(s) within the field of locoregional therapy have subsequently progressed in accordance with RECIST v1.1.\n6. Child-Pugh class A\n7. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1\n8. Adequate hematologic and end-organ function, defined by the following laboratory test results, obtained within 28 days prior to screening:\n\n   1. Hemoglobin ≥ 8.0 g\u002FdL\n   2. Absolute neutrophil count (ANC) ≥ 1,000\u002Fmm3\n   3. Platelet count ≥ 50,000\u002FμL\n   4. Total bilirubin \\\u003C 3.0 mg\u002FdL\n   5. Serum albumin ≥ 2.8 g\u002FdL\n   6. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5 × the upper limit of normal (ULN)\n   7. Prothrombin time in INR ≤ 1.8 × ULN\n   8. Serum creatinine ≤ 2.0 × ULN or calculated creatinine clearance ≥ 40 mL\u002Fmin (using the Cockcroft-Gault equation)\n9. Documented virology status of hepatitis, as confirmed by screening tests for HBV and HCV\n\n   a. Participants with HBV or HCV infection must be treated with antiviral therapy as per institutional practice.\n10. Female participants of childbearing potential must agree to either remain abstinent or use effective contraception (with a failure rate of \\\u003C1% per year) since signing of the informed consent form until at least 6 months after the last study drug administration.\n11. Male participants must agree to remain abstinent or use a condom and refrain from donating sperm since signing of the informed consent form until at least 6 months after the last study drug administration.\n\nExclusion Criteria:\n\n1. Fibrolamellar carcinoma or sarcomatoid carcinoma\n2. Receipt of 2 or more prior systemic therapy for advanced HCC. Additional prior systemic therapies used as adjuvant or local therapy are allowed.\n3. Receipt of other first-line systemic therapy than immune checkpoint inhibitor-based regimen\n4. Receipt of prior radiation therapy to liver\n\n   a. Participants are excluded if the potential radiation field overlaps with a previously irradiated area.\n5. Receipt of locoregional therapy for HCC within 28 days prior to initiation of study treatment or non-recovery from complications due to the procedure (radiofrequency ablation, microwave ablation, cryoablation, trans-arterial embolization including chemo- and radio-embolization, or radiation therapy).\n\n   a. A 7-day washout is permitted for palliative radiation to bone lesions\n6. Active or history of autoimmune disease or immune deficiency, including, but not limited to, myasthenia gravis, myositis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, or multiple sclerosis with following exceptions:\n\n   1. Patients with hypothyroidism stable on hormone replacement\n   2. Controlled type 1 diabetes mellitus and on an insulin regimen\n   3. Any chronic skin condition that does not require systemic therapy\n7. Prior allogeneic stem cell or solid organ transplantation\n8. Any condition requiring systemic treatment with either corticosteroids (\\> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days prior to initiation of study treatment\n9. History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins\n10. Having active brain metastasis or leptomeningeal metastasis\n11. Moderate to severe or intractable ascites\n12. Presence of hepatic encephalopathy\n13. History of malignancy other than HCC within 2 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate \\>90%)\n14. Uncontrolled severe medical comorbidities, including significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to the initiation of study treatment, unstable arrhythmia, or unstable angina or any significant medical illness or abnormal laboratory findings that, in the investigator's judgement, would increase the risk to the participant associated with study participation\n15. Female participants who are pregnant or breastfeeding or male or female participants of reproductive potential who are not willing to employ effective birth control from screening to 6 months after the last study drug administration\n16. Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements",{"count":174,"type":20},128,[56],"In the present study, we aim to investigate the efficacy and safety of concurrent therapy of Immunotherapy based combination therapy and Radiotherapy in patients with advanced HCC showing macrovascular invasion.",[178],"Advanced Hepatocellular Carcinoma (HCC)","2025-12-24",{"date":181,"type":34},"2025-12-26",{"date":183,"type":34},"2025-04-15",{"date":185,"type":20},"2028-08-06",{"name":40,"class":41},2,{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":194,"eligibilityCriteria":195,"healthyVolunteers":11,"sex":196,"minAge":17,"maxAge":83,"enrollmentInfo":197,"targetDuration":4,"studyType":21,"phases":199,"briefSummary":200,"conditions":201,"keywords":202,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":42},"100606129","phase-2-secondary-cytoreductive-surgery-after-chemotherapy-for-recurrent-epithelial-ovarian-cancer-100606129","NCT07171528","Secondary Cytoreductive Surgery After Chemotherapy for Recurrent Epithelial Ovarian Cancer","Secondary Cytoreductive Surgery After Chemotherapy for Recurrent Epithelial Ovarian Cancer: A Phase II Randomized Controlled Trial","KOV-02S","\\[Inclusion Criteria\\]\n\n1. Patients with histologically confirmed epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.\n2. Patients with recurrent ovarian cancer who have received platinum-based chemotherapy (3 or 4 cycles) and were deemed unsuitable for secondary cytoreductive surgery due to a negative AGO score according to the DESKTOP-III trial.\n3. Patients with recurrent ovarian cancer who have responded to chemotherapy (Complete Response, Partial Response, or Stable Disease).\n4. The patient's disease must have recurred after platinum-based therapy, and be defined as platinum-sensitive, meaning progression occurred more than 6 months (180 days) after the last administration of platinum-based therapy.\n5. Patients aged 19 years or older at the time of providing informed written consent.\n6. Patients with an ECOG (Eastern Cooperative Oncology Group) Performance Status of 0-2 within 28 days prior to clinical trial allocation.\n7. Women who are medically unable to conceive or, if of childbearing potential, must agree to follow contraception guidelines during the treatment period.\n8. The participant (or their legally authorized representative) must provide informed written consent regarding the trial.\n9. The participant may consent to the secondary use of clinical information for future biomedical research. However, refusal to share clinical information for future research does not affect participation in the main trial.\n10. The participant must have adequate organ function as defined in the table below. Specimens must be collected within 28 days.\n\n1\\) Adequate bone marrow function defined as\n\n* White Blood Cell (WBC)≥ 2,500\u002F㎕\n* Platelet (PLT)≥ 100,000\u002F㎕\n* Hemoglobin (H)≥ 8 g\u002Fdl (after correction in cases of simple iron-deficiency anemia) 2) Adequate renal function defined as\n* Creatinine or Creatinine Clearance (Cr or CrCl) or Glomerular filtration rate (GFR) (GFR can also be used instead of Cr or CrCl)\n\n  * Creatinine ≤ 1.5 mg\u002FdL or within 1.5 times the upper limit of normal (ULN)\n  * CrCl ≥ 30 mL\u002Fmin or GFR-EPI ≥ 30 mL\u002Fmin\u002F1.73m² 3) Adequate liver function defined as\n* Total Bilirubin≤ 1.5 x ULN\n* AST (SGOT) and ALT (SGPT)≤ 2.5 x ULN (for patients with liver metastasis, ≤ 5.0 x ULN) 4) No Significant dysfunction in Heart, Lungs, etc.\n\n  * No abnormalities in preoperative pulmonary function tests, electrocardiograms (ECG), or chest X-rays.\n  * For patients with a history of cardiac or pulmonary diseases, a collaborative evaluation with cardiology or pulmonology must confirm that surgery is feasible.\n\nALT(SGPT) = alanine aminotransferase (serum glutamic pyruvic transaminase) AST(SGOT) = aspartate aminotransferase (serum glutamic oxaloacetic transaminase) GFR = glomerular filtration rate; ULN = upper limit of normal\n\n\\[Exclusion Criteria\\]\n\n1. Patients with non-epithelial ovarian cancer or borderline ovarian tumors.\n2. Patients with recurrent ovarian cancer who are not suitable for platinum-based chemotherapy.\n3. Patients over 80 years of age.\n4. Patients with a clinically assessed life expectancy of less than 3 months.\n5. Patients deemed unsuitable for secondary cytoreductive surgery due to clinical findings (e.g., severe adhesions, bowel obstruction, fistula, perforation, or other conditions making surgery infeasible).\n6. Patients with inadequate, cardiac, pulmonary, hepatic, renal, or bone marrow function for surgery.\n7. Patients with uncontrolled active infections.\n8. Patients diagnosed with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML), or those exhibiting features suggestive of MDS\u002FAML.\n9. Patients whose primary disease is an extra-abdominal condition that is expected to be a major cause of morbidity or mortality.\n10. Patients with active central nervous system metastasis or carcinomatous meningitis. Patients with a history of brain metastasis must be radiologically stable.\n11. Patients with infections requiring systemic treatment (parenteral administration of antibiotics for bacterial, antifungal, or antivirals).\n12. Patients with uncontrolled active tuberculosis (TB) within one month before treatment initiation.\n13. Patients with psychiatric disorders that may interfere with their ability to comply with the trial, including those diagnosed with mental illness or substance abuse disorders.\n14. Female patients who have not undergone a hysterectomy and have a positive urine pregnancy test within 14 days prior to study allocation. For women of childbearing potential, even if the screening urine pregnancy test is negative, additional pregnancy tests may be conducted at the discretion of the investigator at the time of surgery or chemotherapy initiation Pregnancy tests are not required for women who have undergone hysterectomy or are otherwise confirmed to be infertile.\n15. Patients who are currently breastfeeding.\n16. Patients with a history of allogeneic tissue\u002Fsolid organ transplantation, bone marrow transplantation, or dual umbilical cord blood transplantation.\n17. Patients who, in the judgment of the principal investigator, are unlikely to comply with the trial procedures, restrictions, and requirements.\n18. Patients currently enrolled in another clinical trial and receiving an investigational drugs or medical device, or those who have used any investigational drugs or device within 3 weeks prior to the first administration of the study treatment.\n19. Patients who have entered the follow-up phase of a clinical trial may participate in this study only if at least 3 weeks have passed since their last use of an investigational drug or device.","FEMALE",{"count":198,"type":20},80,[56],"To compare outcomes between the CRS group and the control group in patients with recurrent epithelial ovarian cancer who have undergone chemotherapy",[90],[203,204,205,206,207],"ovarian cancer","Recurrent ovarian cancer","Epithelial Ovarian Cancer","platinum sensitive recurrent ovarian cancer","secondarycytoreductive surgery","2025-09-08",{"date":210,"type":34},"2025-09-12",{"date":212,"type":20},"2025-09-10",{"date":214,"type":20},"2033-12-31",{"name":40,"class":41},{"id":217,"slug":218,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":4,"eligibilityCriteria":222,"healthyVolunteers":223,"sex":51,"minAge":17,"maxAge":4,"enrollmentInfo":224,"targetDuration":4,"studyType":21,"phases":226,"briefSummary":227,"conditions":228,"keywords":230,"overallStatus":132,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":239,"locationsCount":42},"100602623","intravesical-hyaluronic-acid-ha-for-preventing-radiation-cystitis-on-bladder-cancer-100602623","NCT07125924","Intravesical Hyaluronic Acid (HA) for Preventing Radiation Cystitis on Bladder Cancer","Intravesical Hyaluronic Acid (HA) for Preventing Radiation Cystitis on Bladder Cancer : A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Pathologic confirmed Muscle-Invasive Urothelial Carcinoma I. Clinical stage: T2-T4a MIBC II. No or limited nodal involvement (N0 or partial N1, only isolated or regional) III. No distant metastasis (M0) IV. Transurethral resection of bladder tumor (TURBT): Maximal TURBT is available \\> Most tumors must be resected, and residual disease should be minimized.\n\n   V. Preserved bladder function is required: patients must have normal bladder capacity and maintain adequate voiding function.\n\n   VI. Unifocal or localized tumor (except multifocal) VII. No extensive carcinoma in situ (CIS)\n2. Age ≥ 19\n3. Karnofsky performance score (KPS) ≥ 70 or ECOG performance status 0\\~2\n4. Patients who are candidates for bladder-preserving therapy, specifically those scheduled to undergo concurrent chemoradiotherapy (CCRT) instead of radical cystectomy.\n5. Patients scheduled to receive radiotherapy in combination with one or more of the following chemotherapeutic agents prior to study enrollment: Cisplatin-based chemotherapy (e.g. weekly cisplatin), Gemcitabine or 5-FU\u002Fmitomycin, in accordance with standard clinical practice.\n6. Written informed consent obtained from the patients prior to study participation\n\nExclusion Criteria:\n\n1. Present of distant metastasis (M1)\n2. Tumor invasion beyond the bladder wall into adjacent organs (T4b)\n3. Non-urothelial carcinoma (including histologic variant) or predominant of non-urothelial components in mixed histology\n4. Medically inoperable status or poor general condition (ECOG performance status \\> 2)\n5. History of active cystitis or recurrent urinary tract infections within the past 6 months\n6. Known hypersensitivity to hyaluronic acid or related compounds\n7. Any condition in which, in the investigator's judgment, administration of the study drug or procedure is deemed inappropriate\n8. Pregnant or breastfeeding women, or women of childbearing potential who are unable or unwilling to use adequate contraception during the study period",true,{"count":225,"type":20},54,[23],"To evaluate the efficacy and safety of intravesical hyaluronic acid (HA) instillation therapy for the prevention of radiation-induced cystitis in patients undergoing radiotherapy for bladder cancer.",[59,229],"Radiation Cystitis",[231,229,63,232],"Hyaluronic acid","Prevention","2025-08-09",{"date":235,"type":34},"2025-08-15",{"date":237,"type":20},"2025-08-22",{"date":139,"type":20},{"name":40,"class":41},{"id":241,"slug":242,"hasResults":11,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":4,"eligibilityCriteria":246,"healthyVolunteers":11,"sex":196,"minAge":82,"maxAge":247,"enrollmentInfo":248,"targetDuration":4,"studyType":21,"phases":250,"briefSummary":251,"conditions":252,"keywords":4,"overallStatus":132,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":4},"100595878","a-study-to-evaluate-the-effectiveness-of-a-web-based-tool-for-fertility-preservation-in-cancer-patients-100595878","NCT07038174","A Study to Evaluate the Effectiveness of a Web-based Tool for Fertility Preservation in Cancer Patients","A Study for Development and Testing of Fertility Preservation Decision Aid for Young Cancer Patients","Inclusion Criteria:\n\n* Female cancer patients aged 18 to 40 who received treatment at the National Cancer Center between June 2025 and December 2025\n* Voluntarily agreed to participate in the study\n* Able to read, write, and communicate in Korean without difficulty\n\nExclusion Criteria:\n\n* Patients who had already lost fertility prior to participating in the study\n* Patients who had already undergone, or were scheduled to undergo, a specific fertility preservation procedure","40 Years",{"count":249,"type":20},32,[23],"\\[Background\\] The number of young cancer patients is increasing, and they may experience impairment or loss of reproductive function due to cancer treatments such as surgery, radiation therapy, and chemotherapy.\n\nAlthough various medical methods to preserve fertility have been developed, due to the complexity and medical specialization of these methods, there is an urgent need to support understanding and decision-making regarding these options in clinical practice.\n\nWhile referrals to fertility specialists for counseling are possible, most young cancer patients do not receive such consultations before treatment. Even those who do often report decisional conflict due to confusion about the information and difficulty in reflecting personal values in the decision-making process.\n\nAlthough decision aids have been developed in other countries, cultural, linguistic, and healthcare system differences make it difficult to apply these tools in Korea.\n\nTherefore, there is a need to develop a decision aid tailored to female cancer patients in Korea for use in local clinical settings to support fertility preservation decisions.\n\n\\[Study Objective\\] To develop a web-based decision aid and evaluate its impact on decisional conflict, fertility preservation-related knowledge, decision self-efficacy, depression, and quality of life, in order to assess the effectiveness of the decision aid.\n\n\\[Study Hypothesis\\]\n\nThe use of a web-based decision aid for fertility preservation will:\n\nReduce decisional conflict experienced by cancer patients during the decision-making process; Improve fertility preservation-related knowledge and decision self-efficacy; Reduce levels of depression and improve quality of life.\n\n\\[Study Plan\\]\n\n1. Study Design\n\n   * Randomized clinical study\n   * Prospective study\n   * Two-arm randomized controlled trial (RCT)\n\n     2\\. Study Method Female cancer patients visiting the outpatient clinic of the National Cancer Center will be screened to determine eligibility based on inclusion and exclusion criteria.\n\nPatients who meet the criteria and voluntarily agree to participate will be enrolled in the study.\n\nParticipants will be randomly assigned to either the intervention group (who will use the decision aid) or the control group (who will receive standard cancer treatment as planned at the Cancer Center without any special tools).\n\nThe decision aid will be provided to the intervention group immediately after randomization. The control group will not receive any additional tools.\n\nOutcomes will be measured at three time points for the intervention group: before the intervention (T0), one week after the intervention (T1), and one month after the intervention (T2).\n\nFor the control group, measurements will be taken at the same time points: immediately after randomization (T0), one week later (T1), and one month later (T2).",[253,254],"Infertility, Female","Neoplasms","2025-06-23",{"date":257,"type":34},"2025-06-26",{"date":259,"type":20},"2025-06-30",{"date":261,"type":20},"2025-12-31",{"name":40,"class":41},{"id":264,"slug":265,"hasResults":11,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":4,"eligibilityCriteria":269,"healthyVolunteers":11,"sex":51,"minAge":52,"maxAge":270,"enrollmentInfo":271,"targetDuration":4,"studyType":21,"phases":273,"briefSummary":274,"conditions":275,"keywords":277,"overallStatus":132,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":282,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":4},"100596135","knowledge-enhanced-digital-intervention-to-prevent-low-anterior-resection-syndrome-100596135","NCT07041515","Knowledge-enhanced Digital Intervention to Prevent Low Anterior Resection Syndrome","A Randomized, Multicenter Clinical Trial to Evaluate the Feasibility and Utility of a Postoperative Management App for Patients Undergoing Rectal Resection","Inclusion Criteria:\n\n1. Adults aged 20-70 years\n2. Patients scheduled for anal-sparing rectal resection or stomy repair diagnosed with rectal cancer (within 15 cm from Anal Verge)\n3. Patients with an expected survival period of 1 year or more\n4. Patients or their primary caregivers use smartphones (apps)\n5. Patients who are aware of their own status and can provide consent for this study\n\nExclusion Criteria:\n\n1. If you are receiving chemotherapy or radiotherapy at the time of consent\n2. If you are scheduled for major colectomy such as total colectomy or partial colectomy in addition to rectal resection\n3. If you cannot be contacted by phone\n4. If you cannot read and understand Korean\n5. If you cannot provide consent based on clear and sufficient information","70 Years",{"count":272,"type":20},320,[23],"Low anterior resection syndrome refers to changes in bowel habits such as frequent defecation, urgent defecation, and fecal incontinence, which result in decreased bowel function. It occurs very commonly after surgery for colorectal cancer, especially rectal cancer, and symptoms appear severely immediately after surgery, followed by a recovery process. It is known that symptoms improve significantly after one year of surgery, but in some patients, symptoms persist, which significantly affects the quality of life and causes social problems.\n\nThere is no established treatment method for low anterior resection syndrome, and accurate evaluation and customized treatment are required according to the patient's surgical or radiotherapy treatment content and symptoms. It is also important to monitor the change in symptoms during the treatment process, and a customized step-by-step treatment strategy for such patients is required. However, such a customized step-by-step treatment strategy for such patients is very complex, and there are no clear guidelines to date, and the research design for some clinical trials has been recently reported.\n\nThe purpose of this study was to develop an app-based Patient-Reported Outcome (PRO) standardized questionnaire for patients after rectal cancer surgery to systematically collect and monitor symptom information, establish a multidisciplinary management plan tailored to patients, and provide education and treatment to improve the quality of life of rectal cancer survivors. A management program utilizing a research device (app) can reduce the incidence of Major LARS after rectal cancer surgery compared to standard treatment.",[276],"Rectal Neoplasm",[278,279,280],"rectal neoplasm","low anterior resection syndrome","Patient Reported Outcome","2025-06-18",{"date":283,"type":34},"2025-06-27",{"date":285,"type":20},"2025-07-01",{"date":287,"type":20},"2032-01-30",{"name":40,"class":41},{"id":290,"slug":291,"hasResults":11,"nctId":292,"briefTitle":293,"officialTitle":294,"acronym":4,"eligibilityCriteria":295,"healthyVolunteers":11,"sex":51,"minAge":52,"maxAge":4,"enrollmentInfo":296,"targetDuration":4,"studyType":21,"phases":298,"briefSummary":299,"conditions":300,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":42},"100529016","intraductal-radiofrequency-thermoablation-and-radiotherapy-combined-treatment-for-extrahepatic-cholangiocarcinoma-100529016","NCT06168292","Intraductal Radiofrequency Thermoablation and Radiotherapy Combined Treatment for Extrahepatic Cholangiocarcinoma","Intraductal Radiofrequency Thermoablation and Radiotherapy Combined Treatment for Extrahepatic Cholangiocarcinoma: A Prospective, Single-arm, Multicenter Study","Inclusion Criteria:\n\n1. Patients 20 years of age or older, who voluntarily agree to participate in the study and sign the informed consent.\n2. Patients with cytopathologically diagnosed inoperable extrahepatic cholangiocarcinoma\n\nExclusion Criteria:\n\n1. Patients who refuse to sign the informed consent\n2. Patients with metastatic cancer (stage IV) or malignant ascites\n3. Patients with intrahepatic cholangiocarcinoma\n4. Patients who are unable to undergo endoscopic procedures as determined by the investigator.\n5. Patients with a life expectancy of 3 months or less\n6. Patients with ID-RFA contraindications: pacemaker, pregnancy, uncorrected bleeding tendency (PT INR \\> 1.5, platelets \\\u003C 50,000\u002Fmm3)",{"count":297,"type":20},53,[23],"\\[Study objectives\\] To evaluate the efficacy and safety of the combined treatment of radiotherapy and endoscopic intraductal radiofrequency ablation in patients with locoregional extrahepatic cholangiocarcinoma.",[301,302,303],"Biliary Tract Carcinoma","Radiotherapy","Radio-frequency Ablation","2025-06-16",{"date":306,"type":34},"2025-06-19",{"date":308,"type":34},"2024-04-01",{"date":310,"type":20},"2030-06-30",{"name":40,"class":41},{"id":313,"slug":314,"hasResults":11,"nctId":315,"briefTitle":316,"officialTitle":317,"acronym":318,"eligibilityCriteria":319,"healthyVolunteers":11,"sex":51,"minAge":17,"maxAge":4,"enrollmentInfo":320,"targetDuration":4,"studyType":21,"phases":322,"briefSummary":323,"conditions":324,"keywords":328,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":329,"lastUpdatePostDateStruct":330,"startDateStruct":331,"completionDateStruct":333,"leadSponsor":335,"locationsCount":42},"100526527","phase-2-tripegfilgrastim-trial-to-reduce-the-risk-of-severe-neutropenia-in-patients-with-unresectable-pancreaticobiliary-cancers-100526527","NCT06135896","Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers","An Open-label, Randomized, Multicenter, Phase II Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers","Dulastin","Inclusion Criteria:\n\n* Patients aged at least 19 years old, diagnosed with unresectable pancreaticobiliary cancer, and scheduled to receive chemotherapy using nal-IRI\u002F5-FU\u002FLV combination chemotherapy\n\nExclusion Criteria:\n\n* Patients who refuse to sign the consent form Patients who have previously experienced severe neutropenia during chemotherapy",{"count":321,"type":20},98,[56],"* Clinical trial phase: Phase 2\n* Intervention model: Control group\n* Group allocation: Randomized controlled trial\n* Research perspective: Prospective study\n* Participating centers: Multicenter study\n* Definition of the intervention period: Based on the RECIST 1.1 guidelines, patients will receive treatment until dropout due to disease progression or unacceptable toxicity related to the trial drug. Patients will be followed up with to assess survival every 2 months until either death or the end of the trial, whichever is first.\n* The intervention period is from the date of IRB approval to December 31st, 2025\n* The follow-up duration is one year, and the statistical analysis duration is six months\n* The total research period is from the date of IRB approval to June 30th, 2026",[325,326,327],"Unresectable Pancreatic Cancer","Unresectable Bile Duct Carcinoma","Unresectable Biliary Tract Carcinoma",[325,326,327],"2025-06-15",{"date":281,"type":34},{"date":332,"type":34},"2024-01-16",{"date":334,"type":20},"2026-06-30",{"name":40,"class":41},{"id":337,"slug":338,"hasResults":11,"nctId":339,"briefTitle":340,"officialTitle":341,"acronym":4,"eligibilityCriteria":342,"healthyVolunteers":11,"sex":51,"minAge":343,"maxAge":344,"enrollmentInfo":345,"targetDuration":4,"studyType":21,"phases":347,"briefSummary":348,"conditions":349,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":352,"startDateStruct":354,"completionDateStruct":356,"leadSponsor":357,"locationsCount":358},"100590617","development-and-application-of-intervention-program-to-improve-mental-health-and-quality-of-life-of-solid-tumor-survivors-and-caregivers-100590617","NCT06969742","Development and Application of Intervention Program to Improve Mental Health and Quality of Life of Solid Tumor Survivors and Caregivers","Development and Clinical Application of Intervention Program to Improve Mental Health and Quality of Life of Pediatric Solid Tumor Survivors and Caregivers, a Multicenter, Experimental Group, Pre-and-post Evaluation Intervention Study","Inclusion Criteria:\n\n* Those between the ages of 10 and 24, and diagnosed with pediatric solid tumor, who are undergoing treatment or survivors who have completed the treatment and the treatment end date is within 2 years.\n* Parent or legal guardian who is a primary caregiver to children and adolescent patient of acute-transitional phase.\n* Those whose cognitive ability is capable of verbal counseling and who agrees to the evaluation assessment.\n\nExclusion Criteria:\n\n* Those who disagree to participate as a research subject.\n* Those whose psycho-emotional state requires professional treatment or medical conditions precludes intervention.\n* Those undergoing treatment and children and adolescent survivors of acute-transitional phase, whose prior intelligence assessment FSIQ score is less than 70. However, if the GAI score is 70 or higher, participation is possible after the principal investigator's interview, with linguistic competence taken into consideration.\n\nElimination Criteria:\n\n* Those who withdraw consent of this research.\n* Those who have difficulty participating due to worsening of disease or decease of patient.","10 Years","24 Years",{"count":346,"type":20},120,[23],"The research team will assess the psychological abilities like cognitive(how you think and figure things out) and psycho-social(the well-being at the intersection of the internal workings and external experience) functions of young patients who are diagnosed with solid tumor and their primary caregivers. After assessing the psychological abilities, the research team will provide counseling and educational sessions developed by the team. The sessions are provided on a 1:1 basis to each of the participants to verify whether the sessions helped to improve the quality of life, including mental health.",[350],"Pediatric Solid Tumors","2025-05-12",{"date":353,"type":34},"2025-05-14",{"date":355,"type":34},"2023-12-27",{"date":72,"type":20},{"name":40,"class":41},3,{"id":360,"slug":361,"hasResults":11,"nctId":362,"briefTitle":363,"officialTitle":363,"acronym":364,"eligibilityCriteria":365,"healthyVolunteers":11,"sex":51,"minAge":17,"maxAge":366,"enrollmentInfo":367,"targetDuration":4,"studyType":21,"phases":369,"briefSummary":370,"conditions":371,"keywords":374,"overallStatus":132,"whyStopped":4,"lastUpdateSubmitDate":376,"lastUpdatePostDateStruct":377,"startDateStruct":378,"completionDateStruct":380,"leadSponsor":382,"locationsCount":4},"100590787","necessity-of-tsh-suppression-therapy-in-active-surveillance-for-thyroid-cancer-patients-100590787","NCT06971965","Necessity of TSH Suppression Therapy in Active Surveillance for Thyroid Cancer Patients.","MAeSTro-TSH","Inclusion Criteria:\n\n* Thyroid nodule of 1.0 cm or less confirmed as Bethesda category V (suspicious for PTC) or VI (PTC) based on cytopathological examination, or Bethesda category III (atypia of undetermined significance) with a confirmed BRAF V600E mutation.\n* Patients with no evidence of distant metastasis, cervical lymph node metastasis, recurrent laryngeal nerve invasion, or tracheal invasion. Additionally, no evidence of extrathyroidal extension (ETE) should be present, and the tumor must not belong to high-risk subtypes of PTC (e.g., diffuse sclerosing, columnar cell, or solid subtype).\n* Non-pregnant women of childbearing potential (confirmed by medical history taking)\n\nExclusion Criteria:\n\n* Hyperthyroidism\n* If the investigator determines that you are not suitable for clinical research participation considering the following comorbidities:\n\n  * Myocardial infarction or cerebrovascular accident within the last three months.\n  * Diseases with limited life expectancy or potentially impairing the patient's ability to comply with at least five years of treatment or follow-up.","79 Years",{"count":368,"type":20},578,[23],"This study is a multicenter randomized controlled trial conducted in Korea. A parallel, two-group randomized design will be with thyroid stimulating hormone suppression therapy group(low TSH group; intervention) is different from the wIthout thyroid stimulating hormone (TSH) suppression therapy group(high TSH group; control).",[372,373],"Thyroid Cancer","Papillary Thyroid Carcinoma",[375],"Active Surveillance","2025-05-07",{"date":353,"type":34},{"date":379,"type":20},"2025-06-02",{"date":381,"type":20},"2032-12-31",{"name":40,"class":41},{"id":384,"slug":385,"hasResults":11,"nctId":386,"briefTitle":387,"officialTitle":388,"acronym":389,"eligibilityCriteria":390,"healthyVolunteers":11,"sex":51,"minAge":82,"maxAge":4,"enrollmentInfo":391,"targetDuration":4,"studyType":21,"phases":393,"briefSummary":394,"conditions":395,"keywords":396,"overallStatus":132,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":400,"startDateStruct":402,"completionDateStruct":403,"leadSponsor":404,"locationsCount":4},"100572255","shared-decision-making-for-determining-treatment-strategies-in-low-risk-thyroid-cancer-100572255","NCT06730893","Shared Decision-Making for Determining Treatment Strategies in Low-Risk Thyroid Cancer","Shared Decision-Making for Determining Treatment Strategies in Low-Risk Thyroid Cancer: a Multicenter Cluster-Randomized Controlled Trial","MAeSTro-SDM","Inclusion Criteria:\n\n* Adults aged 18 years or older with a thyroid nodule of 1.0 cm or less confirmed as Bethesda category V (suspicious for PTC) or VI (PTC) based on cytopathological examination, or Bethesda category III (atypia of undetermined significance) with a confirmed BRAF V600E mutation.\n* Patients with no evidence of distant metastasis, cervical lymph node metastasis, recurrent laryngeal nerve invasion, or tracheal invasion. Additionally, no evidence of extrathyroidal extension (ETE) should be present, and the tumor must not belong to high-risk subtypes of PTC (e.g., diffuse sclerosing, columnar cell, or solid subtype).\n\nExclusion Criteria:\n\n* Patients who cannot undergo regular follow-up or are expected to have difficulties with follow-up.\n* Patients with indeterminate or benign findings on thyroid biopsy.",{"count":392,"type":20},310,[23],"This study is a multicenter cluster-randomized controlled trial conducted in Korea. A parallel, two-group cluster-randomized design will be used to test whether the Shared decision-making Group (SDM; intervention) is different from the Standard Care Group (SC; control).",[372,373],[397,398],"Active surveillance","Shared decision making","2025-04-27",{"date":401,"type":34},"2025-04-30",{"date":351,"type":20},{"date":139,"type":20},{"name":40,"class":41},{"id":406,"slug":407,"hasResults":11,"nctId":408,"briefTitle":409,"officialTitle":410,"acronym":4,"eligibilityCriteria":411,"healthyVolunteers":223,"sex":196,"minAge":82,"maxAge":4,"enrollmentInfo":412,"targetDuration":4,"studyType":21,"phases":413,"briefSummary":414,"conditions":415,"keywords":418,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":425,"lastUpdatePostDateStruct":426,"startDateStruct":428,"completionDateStruct":430,"leadSponsor":431,"locationsCount":42},"100576088","surgical-outcome-of-bcs-using-icg-f-in-breast-cancer-patients-after-preoperative-chemotherapy-100576088","NCT06780735","Surgical Outcome of BCS Using ICG-F in Breast Cancer Patients After Preoperative Chemotherapy","Surgical Outcome of Breast Conserving Surgery Using Indocyanine Green Fluorescence in Breast Cancer Patients After Preoperative Chemotherapy: a Prospective Study","Inclusion Criteria:\n\n* The Patient with locally advanced breast cancer who is eligible for breast-conserving surgery after receiving neoadjuvant chemotherapy\n* Aged over 18 years old\n* ECOG performance status: 0 or 1\n* The patients with written informed consent\n\nExclusion Criteria:\n\n* The patient who requires total mastectomy after receiving neoadjuvant chemotherapy\n* The patient with no residual mass on ultrasonography or only with microcalcifications\n* Pregnant or lactating patient\n* The patient with a disability to understand and provide consent\n* The patient with severe allergic history to indocyanine green\n* Iodine-sensitive patient",{"count":174,"type":20},[23],"Neoadjuvant chemotherapy for advanced breast cancer has led to an increased rate of breast-conserving surgery (BCS) in these patients. As the demand for preoperative localization methods grows among surgeons performing BCS, traditional localization techniques have shown limitations. For non-palpable breast lesions, preoperative localization has commonly been achieved using ultrasound-guided skin markings or needle localization. However, these methods present challenges, including difficulty in depth localization for patients with large breasts and limitations in real-time re-verification during surgery due to air artifacts after incision. Needle localization, although commonly used, is invasive and poses risks such as displacement or detachment of the needle.\n\nIndocyanine green (ICG), a fluorescent dye that appears green to the naked eye and is detectable by near-infrared (NIR) cameras, has been widely and safely used in clinical practice via intravenous or subcutaneous administration. Recently, ICG combined with NIR imaging has been adopted for sentinel lymph node biopsy in breast cancer and melanoma surgeries and is increasingly used as a localization method for various tumors, replacing conventional techniques.\n\nA preliminary study (IRB No. NCC2016-0071) conducted at the institution evaluated ICG injection and NIR fluorescence imaging for tumor localization in early breast cancer patients undergoing BCS. The study demonstrated the efficacy of ICG-based localization in reducing the rate of positive surgical margins.\n\nThe objective of this study is to evaluate the effectiveness of ICG-guided tumor localization with NIR fluorescence imaging in patients with advanced breast cancer treated with neoadjuvant chemotherapy. It is hypothesized that this technique will allow for more accurate tumor excision compared to conventional methods, ultimately improving surgical outcomes.",[416,417],"Breast Neoplasms","Breast Cancer",[419,420,421,422,423,424],"Indocyanine green","Breast conserving surgery","Breast cancer","neoadjuvant chemotherapy","Tumor Localization","Near-Infrared Fluorescence Imaging","2025-03-10",{"date":427,"type":34},"2025-03-13",{"date":429,"type":34},"2023-07-06",{"date":261,"type":20},{"name":40,"class":41},{"id":433,"slug":434,"hasResults":11,"nctId":435,"briefTitle":436,"officialTitle":436,"acronym":4,"eligibilityCriteria":437,"healthyVolunteers":223,"sex":196,"minAge":82,"maxAge":4,"enrollmentInfo":438,"targetDuration":4,"studyType":21,"phases":440,"briefSummary":441,"conditions":442,"keywords":447,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":450,"lastUpdatePostDateStruct":451,"startDateStruct":453,"completionDateStruct":455,"leadSponsor":456,"locationsCount":42},"100576089","phase-2-photo-medicine-guided-dual-approach-for-reoperation-of-sentinel-lymph-nodes-in-locally-recurrent-breast-cancer-patients-100576089","NCT06780748","Photo-medicine-Guided Dual Approach for Reoperation of Sentinel Lymph Nodes in Locally Recurrent Breast Cancer Patients","Inclusion Criteria:\n\n* Patients with ipsilateral locally recurrent breast cancer who previously underwent ipsilateral axillary surgery.\n* Female patients aged 18 years or older.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Patients who voluntarily decide to participate in the study and provide written informed consent.\n\nExclusion Criteria:\n\n* Patients with distant metastases.\n* Patients who previously underwent ipsilateral mastectomy.\n* Pregnant or breastfeeding women.\n* Patients with a general condition that impairs the ability to understand or provide informed consent.",{"count":439,"type":20},30,[56],"Sentinel lymph node biopsy (SLNB) is essential for staging and treatment planning in early breast cancer patients. As a less invasive procedure, it has replaced axillary lymph node dissection (ALND) by reducing complications and improving patient outcomes. However, the 10-year local recurrence rate for breast cancer is approximately 2-10%, and the role of SLNB in the surgical management of recurrent breast cancer remains unclear.\n\nAccording to the NCCN guidelines and Korean Breast Cancer Treatment Recommendations, surgical management for recurrent breast cancer includes mastectomy and axillary lymph node surgery for patients who have previously undergone breast-conserving surgery and radiotherapy. For axillary recurrence, surgery is recommended if feasible, followed by radiotherapy. Conversely, the ASCO guidelines recommend SLNB for surgically resectable recurrent breast cancer, and recent studies have reported promising outcomes for repeat sentinel lymph node biopsy (reSLNB). Vugts G et al. demonstrated an 80.1% tumor-negative rate with reSLNB, suggesting that ALND could be avoided in many cases.\n\nAlthough reSLNB offers the advantage of reducing unnecessary invasive procedures and associated complications, challenges remain due to disrupted lymphatic pathways in patients who have previously undergone surgery and radiotherapy. Additionally, research on the long-term prognosis of these patients is still limited.\n\nThis study aims to evaluate the detection rate of sentinel lymph nodes using a photo-medicine-based dual localization technique that combines traditional radiotracer methods with indocyanine green-fluorescence (ICG-F) in patients undergoing reSLNB for locally recurrent breast cancer.",[417,443,444,445,446],"Locally Recurrent Breast Cancer","Sentinel Lymph Node Biopsy (SLNB)","Reoperation","ICG (indocyanine Green)",[421,448,444,445,449],"Locally Recurrent Breast cancer","ICG(indocyanine green)","2025-01-13",{"date":452,"type":34},"2025-01-17",{"date":454,"type":34},"2023-08-13",{"date":261,"type":20},{"name":40,"class":41},{"id":458,"slug":459,"hasResults":11,"nctId":460,"briefTitle":461,"officialTitle":462,"acronym":463,"eligibilityCriteria":464,"healthyVolunteers":11,"sex":51,"minAge":17,"maxAge":119,"enrollmentInfo":465,"targetDuration":4,"studyType":21,"phases":467,"briefSummary":468,"conditions":469,"keywords":473,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":479,"lastUpdatePostDateStruct":480,"startDateStruct":482,"completionDateStruct":484,"leadSponsor":486,"locationsCount":42},"100430829","comparison-of-endoscopic-resection-and-surgery-for-early-gastric-cancer-with-undifferentiated-histological-type-100430829","NCT04890171","Comparison of Endoscopic Resection and Surgery for Early Gastric Cancer With Undifferentiated Histological Type","Comparison of Endoscopic Resection and Surgery for Early Gastric Cancer With Undifferentiated Histological Type: a Multicenter Randomized Controlled Trial (ERASE-GC Trial)","ERASE-GC","Inclusion Criteria:\n\n1. Patients who are diagnosed with undifferentiated type EGC (signet ring cell carcinoma, poorly differentiated tubular adenocarcinoma, or poorly cohesive carcinoma) that meets the expanded indication of ESD 1) Tumor confined to the mucosa without ulcer, and size ≤2 cm on endoscopic evaluations 2) No evidence of lymph node metastasis and distant metastasis on abdominal CT scan\n2. Adult patients aged 19-75 years\n3. Patients who had willingness to sign an informed consent form\n\nExclusion Criteria:\n\n1. Patient age: \\\u003C 19 years or age \\> 75 years\n2. Diagnosis and active treatment for other organ cancer except carcinoma in situ and non-melanomatous skin cancer within 5 years\n3. Previous gastrectomy or esophagectomy history\n4. Multiple gastric cancers\n5. Current treatment for serious medical condition which could hinder study participation including severe heart dysfunction, liver cirrhosis, renal failure, chronic obstructive pulmonary disease or asthma, or uncontrolled infection\n6. Inability to provide an informed consent\n7. Inadequate conditions for study enrollment according to the evaluation of study physicians",{"count":466,"type":20},708,[23],"This multi-center, randomized controlled trial is designed to evaluate clinical effectiveness and cost-effectiveness of ESD for undifferentiated type of EGC meeting the expanded indication compared with surgery.",[470,471,472],"Stomach Cancer","Undifferentiated Type","Expanded Indication of Endoscopic Resection",[474,475,476,477,478],"Early gastric cancer","Endoscopic submucosal dissection","Surgery","Undifferentiated type","Expanded indication","2024-12-25",{"date":481,"type":34},"2024-12-27",{"date":483,"type":34},"2021-06-11",{"date":485,"type":20},"2029-02-28",{"name":40,"class":41},{"id":488,"slug":489,"hasResults":11,"nctId":490,"briefTitle":491,"officialTitle":492,"acronym":493,"eligibilityCriteria":494,"healthyVolunteers":11,"sex":51,"minAge":17,"maxAge":270,"enrollmentInfo":495,"targetDuration":4,"studyType":21,"phases":497,"briefSummary":498,"conditions":499,"keywords":502,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":479,"lastUpdatePostDateStruct":504,"startDateStruct":505,"completionDateStruct":507,"leadSponsor":509,"locationsCount":110},"100379010","phase-3-aspirin-use-for-gastric-cancer-prevention-in-the-early-gastric-cancer-patients-100379010","NCT04214990","Aspirin Use for Gastric Cancer Prevention in the Early Gastric Cancer Patients","Effect of Low-dose Aspirin for Stomach Cancer Prevention After Endoscopic Resection of Gastric Neoplasm (EASTERN): a Randomized Controlled Trial","EASTERN","Inclusion Criteria:\n\n* Men and women aged 19-70 years who underwent endoscopic resection for high-grade adenoma or early gastric cancer (category 4 \\[non-invasive high grade neoplasm\\] or category 5 \\[invasive neoplasia\\] according to the Vienna classification of gastrointestinal epithelial neoplasia \\[Schlemper RJ, et al. Gut 2000;47:251-255.\\])\n* Final pathological results after endoscopic resection met the absolute or expanded criteria according to the Japanese Gastric Cancer Treatment guideline 2014 (version 4)\n* Patients who had negative H. pylori status or those who eradicated H. pylori status\n* Willingness to sign an informed consent form\n\nExclusion Criteria:\n\n* Patients who received aspirin for the secondary prevention of cardiovascular diseases or cerebrovascular diseases\n* Regular aspirin uses (more than 3 times a week) with 2 months before screening visit\n* Patients who used anticoagulants or antiplatelet drugs for therapeutic purpose\n* Previous gastrectomy history\n* Current treatment for serious medical condition which could hinder participation (such as severe heart dysfunction, liver cirrhosis, renal failure, COPD or bronchial asthma, or uncontrolled infection)\n* High risk patients for bleeding complications (cerebral aneurysm, vascular malformation, esophageal or gastric varices, or hemophilia, etc)\n* Active peptic ulcer disease (patients who treated peptic ulcer completely could be enrolled)\n* Diagnosis and active treatment for other organ cancer (except carcinoma in situ, and non-melanoma skin cancer) within 5 years\n* Non-curative resection of early gastric cancer after endoscopic resection\n* Aspirin allergy or contraindication of aspirin use\n* Pregnant or lactating women\n* Alcoholism, drug abuse\n* Inadequate patients for study enrollment according to the evaluation of the study physician\n* Inability to provide an informed consent\n* Patients who took a 28-day run-in-period medication less than 80%",{"count":496,"type":20},1700,[87],"This study aimed to investigate the effect of low-dose (100 mg) asprin on the prevention of gastric cancer in the early gastric cancer patients with negative H. pylori status who underwent endoscopic submucosal dissection.",[500,501],"Aspirin","Gastric Cancer",[500,503,475],"Gastric cancer prevention",{"date":481,"type":34},{"date":506,"type":34},"2020-02-15",{"date":508,"type":20},"2032-03-31",{"name":40,"class":41},{"id":511,"slug":512,"hasResults":11,"nctId":513,"briefTitle":514,"officialTitle":515,"acronym":4,"eligibilityCriteria":516,"healthyVolunteers":11,"sex":51,"minAge":17,"maxAge":4,"enrollmentInfo":517,"targetDuration":4,"studyType":21,"phases":518,"briefSummary":519,"conditions":520,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":522,"lastUpdatePostDateStruct":523,"startDateStruct":525,"completionDateStruct":527,"leadSponsor":529,"locationsCount":530},"100528112","phase-2-a-randomized-phase-ii-study-of-laze-rtinib-alone-versus-lazertinib-plus-bevacizumab-for-nsclc-with-egfr---smoker-100528112","NCT06156527","A Randomized Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & Smoker","A Randomized Phase II Study of LAZE Rti N ib Alone Versus Lazertinib Plus Beva C Izumab for A Dvanced Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor Activating Mutations and Smoking History","Inclusion Criteria:\n\n1. Histologically confirmed patients with locally progressive or metastatic non-small cell lung cancer (IIIB or IV) who have not been diagnosed as squamous cell carcinoma.\n2. Patients with one or more measurable lesions in accordance with the RECIST criteria (Version 1.1), tumor lesions located at the previous irradiation site, are considered measurable if progress has been made in those lesions.\n3. Patients with institutionalized EGFR mutation (exon 19 deletion or L858R)\n4. Patients with a history of smoking, including those who are currently smoking (defined as those who have smoked more than 100 cigarettes in their lifetime)\n5. ECOG PS 0-1 Patient\n6. Patients with appropriate hematological functions ANC≥1,500\u002FuL, hemoglobin≥9.0g\u002FdL, platelet≥100,000\u002FuL\n7. Patients with adequate liver function Total bilirubin \\\u003C 1 x UNL, AST (SGOT) and ALT (SGPT) \\\u003C 2.5 x UNL (If there is an interruption: total bilirubin \\\u003C3 x UNL, AST (SGOT) and ALT (SGPT) \\\u003C5 x UNL)\n8. a patient with appropriate renal function Cr UN UNL, however, can be registered if the creatinine clearance calculated according to the formula Cocroft and Gault is 50 50 ml\u002Fmin outside the normal range.\n\n   Proteinuria test \\\u003C2+ (if 22+ then protein 11g must be in 24-hour urine test)\n9. Patients with a history of receiving radiation therapy must meet the following criteria.\n\n   \\- In the case of direct radiation irradiation to the lung lesion area, it must have elapsed at least 12 weeks from the time of registration.\n   * In the case of chronic radiation therapy for intracoracic bone metastasis, it must be at least 12 weeks from the time of registration.\n   * 2 weeks or more from the time of registration if radiotherapy has been performed on any non-chest area Must be elapsed.\n10. At the time of registration, the date of completion of the previous treatment or procedure must pass the period specified below.\n\n    \\- Surgery (including exploratory\u002Fexperimental thoracotomy): 4 weeks\n\n    \\- Pericardial drainage: 1 week\n\n    \\- pleural adhesion not attributed to anti-species positive substances (including biological response regulators such as Picibanil): 2 weeks\n\n    \\- Tissue biopsy to confirm selection criteria (including biopsy using thoracoscope): 1 week\n    * Procedures for the treatment of trauma (unregistered patients with untreated wounds): 2 weeks\n    * Blood transfusion, hematopoietic growth factor administration: 2 weeks\n    * The puncture and aspiration cell test: 1 week\n    * Administration of other clinical trial medications: 4 weeks\n11. Women in childbearing age should be negative in serum or urine pregnancy tests within 7 days prior to test treatment.\n12. Male and childbearing female test subjects with female partners' pregnancy must agree to use the following two high-efficiency test methods for at least 180 days after the last dose of the assigned treatment is administered. Bevacizumab can also damage a woman's reproductive ability. Therefore, women who have entered the bevacizumab combination group should be preceded by discussions on preserving the reproductive ability of women who are likely to become pregnant before treatment - asceticism\n\n    \\- tubal ligation\n\n    \\- Hormone contraceptives that do not cause drug interactions (such as Mirena)\n    * Medroxyprogesterone injection (Depo-Provera)\n    * Copper bands and intrauterine devices\n    * a partner's vasectomy\n    * Partner's use of condoms\n13. Patients who have agreed to the clinical trial-\n\nExclusion Criteria:\n\n\\- 1) Patients with other malignant tumors except lung cancer within the past three years (except for properly treated cervical epithelial cancer, basal or squamous cell skin cancer, thyroid cancer, and topical prostate cancer surgically treated for healing purposes).\n\n2\\) Patients with a history of bleeding above Grade 2 (with blood above Grade 2) 2.5mL within 3 months of registration defined as the above bright red blood.) 3) chemotherapy for advanced lung cancer in the past or other systemic anticancer drugs (single-clone antibodies or Patients with tyrosine kinase inhibitors) (However, pre- and post-operative assisted chemotherapy, which ended 6 months before the time of registration, is allowed.) 4) A patient with evidence of invasion of large blood vessels, such as the pulmonary artery or relative vein of a tumor, in contrast examination.\n\n5\\) Patients scheduled to undergo hydrophobic surgery (including infantile catheter insertion) within 24 hours of the first injection of bevacizumab 6) Current or recent (within 10 days prior to the initial injection of bevacizumab) aspirin (\\>325 mg\u002Fday) and patients with oral or injectable anticoagulants or thrombolytic agents for therapeutic purposes (provided that preventive use of anticoagulants is permitted).) 7) Patients currently in use (or unable to discontinue prior to the initial dose of lazertinib) with a drug or natural aid known as a potent CYP3A4 inducer that cannot be discontinued throughout clinical trials before enrollment 8) Any evidence of ILD, drug-induced ILD, past history of radiation interstitial pneumonia requiring steroid treatment, or clinically active ILD 9) Patients undergoing or likely to administer bisphosphonate medication 10) Uncontrolled patients with brain-spinal metastasis (Patients with epilepsy can be registered if they are stabilized asymptomaticly, and treated patients with epilepsy can be registered if they do not currently require steroid treatment.) 11) Patients with clinically significant ophthalmic abnormalities on the surface of the eye (not recommended to use contact lenses) (with corneal perforations or ulcers, symptoms and signs of acute or exacerbated corneal inflammation such as ocular inflammation, tear secretion, blurred vision, eye pain and bleeding) 12) Patients with a history of coagulopathy with hereditary bleeding constitution or risk of bleeding 13) Patients with uncontrolled hypertension (systolic blood pressure \\>150 mmHg and\u002For diastolic \\>100 mmHg) 14) Patients with clinically significant active cardiovascular disease (within 6 months of registration, patients with cerebrovascular accidents and diseases, myocardial infarction, unstable angina, NYHA ClassIIII congestive heart failure, thrombosis, thromboembolism, and severe cardiac arrhythmia that may interfere with drug administration during clinical trials)\n\nThe following heart criteria are not limited to one. :\n\n* Average of corrected QT intervals at rest (QTc intervals corrected by Fredericia formula) \\>470 msec based on QTc values calculated by ECG equipment by the test institution during screening.\n* clinically significant abnormal findings found in the rhythm, conduction, or morphology of the ECG at rest (e.g., complete left block, 3rd degree heart block, 2nd degree heart block)\n* All factors that increase the risk of QTc prolongation or arrhythmia, including heart failure, hypokalemia, family history of congenital QT prolongation syndrome, sudden death of causes under the age of 40 in the immediate family, combined drugs known to prolong QT spacing and induce Torsades de Points (TdP).\n\n  15\\) Patients with non-healing wounds, active digestive ulcers, or fractures 16) Patients with active infections and uncontrolled systemic diseases 17) Patients who have a chemical structure similar to lasertinib and bevacizumab or these substances or who have a history of hypersensitivity to active ingredients or inactive excipients of drugs belonging to the family.\n\n  18\\) Patients who are hypersensitive to CHO (animal cell line from the uterus of Chinese hamsters) cell products or other recombinant human body or humanized antibodies.\n\n  19\\) Pregnant or lactating women",{"count":346,"type":20},[56],"Using gefitinib or Osimertinib, an EGFR tyrosine kinase inhibitor (TKI), in patients with active mutations in epithelial cell growth factor receptors (EGFR), 70% response rate (CR+PR) and 90% disease control rate (CR+PR+SD) compared to the current non-small cell therapy, which is significant in the EFRT treatment. However, resistance causes recurrence in most patients. Therefore, it is necessary to develop a more effective treatment. Recently, in Japan, combined allotinib and bevacizumab therapy as primary therapy in non-small cell lung cancer patients with EGFR mutation improved PFS statistically significantly compared to allotinib monotherapy, suggesting the possibility of a new treatment (Hazard ratio 0.605, 95% CI 0.417-0.877, P=0.016). In addition, subsequent osmutinib and bevacizumab combination therapy showed a significant difference in PFS in the smoker group, although they did not show significant improvement in PFS in the entire patient group. (Hazard ratio 0.605, 95% CI 0.417-0.877, P=0.016). Since EGFR mutated lung cancer is highly frequent in Korea, it is necessary to develop more effective treatments for such patients. Therefore, we propose this clinical trial to find out the efficacy of lasertinib and bevacizumab combination therapy.",[521],"Lazertinib","2023-11-27",{"date":524,"type":34},"2023-12-05",{"date":526,"type":34},"2023-09-05",{"date":528,"type":20},"2026-12-31",{"name":40,"class":41},5,{"id":532,"slug":533,"hasResults":11,"nctId":534,"briefTitle":535,"officialTitle":536,"acronym":4,"eligibilityCriteria":537,"healthyVolunteers":223,"sex":51,"minAge":4,"maxAge":4,"enrollmentInfo":538,"targetDuration":540,"studyType":541,"phases":4,"briefSummary":542,"conditions":543,"keywords":547,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":549,"lastUpdatePostDateStruct":550,"startDateStruct":552,"completionDateStruct":554,"leadSponsor":555,"locationsCount":42},"100514760","development-of-asian-consortium-for-data-collection-and-clinical-trial-of-cns-tumors-100514760","NCT05982691","Development of Asian Consortium for Data Collection and Clinical Trial of CNS Tumors","National Cancer Center Korea","Inclusion Criteria:\n\n* A patient who was diagnosed with CNS GCT and agreed to participate in the research between 2022-2027.\n\n  * Patients diagnosed between 2016-2022 can be enrolled if the participating institute has IRB approval for recruiting these patients as separate IRB document (Seoul Asan Hospital) or by comprehensive IRB document (Singapore NCC, Taiwan Medical University), or by recruitment on the basis of acquirement of the consent form for research (NCC, Korea).\n\n    * The age at the time of diagnosis is 0\\\u003C ≤40 years\n\n      * A patent who has been diagnosed with the relevant tumor via an operation or a biopsy ⑤ In the case of CNS germinoma, a biopsy may not have been performed on a patient. In this case, the patient may register as germinoma if he or she meets the following criteria: -Germinoma is strongly suspected radiologically, and a tumor marker from serum or cerebrospinal fluid (CSF) has not increased above the institute's reference normal value; -Germinoma is suspected radiologically, and a tumor marker from serum or CSF has elevated above the institute's reference normal value (tumor markers may be AFP or hCG)\n\nExclusion Criteria:\n\n① The patient or the guardian of the patient did not consent to participate.",{"count":539,"type":20},400,"1 Year","OBSERVATIONAL","\\\u003CPurpose of the Research\\>\n\n* Primary Establishing an Asian consortium to establish a database of pediatric CNS tumors in the prospective manner The target disease of this research focuses on pediatric tumors, and initially the registration of patients with CNS GCT will begin first.\n* Secondary Developing clinical protocols for pediatric CNS tumors based in Asia\n\n\\\u003CDuration of Research Participation\\> Registration period for research subjects: 2022-08-01 - 2027-12-31 Duration of medical records to be utilized: to 2030-12-31 Total projected duration of research: IRB approved to 2032-12-31 Interim assessment of data quality and integrity: 6 Mo after Data collection Evaluation for the Adaptation of Protocols: 1 and 2 years after the initiation of the study Analysis of Quality of Life and other questionnaires: 3 and 5 years Interim Analysis of all data: 5 years (2027) Final analysis of treatment outcome: 2032",[544,545,546],"CNS Germinoma","CNS Tumor","Asian Consortium",[548,545,546],"CNS germinoma","2023-08-07",{"date":551,"type":34},"2023-08-08",{"date":553,"type":34},"2022-08-05",{"date":381,"type":20},{"name":40,"class":41},{"id":557,"slug":558,"hasResults":11,"nctId":559,"briefTitle":560,"officialTitle":561,"acronym":4,"eligibilityCriteria":562,"healthyVolunteers":11,"sex":51,"minAge":52,"maxAge":83,"enrollmentInfo":563,"targetDuration":4,"studyType":21,"phases":565,"briefSummary":566,"conditions":567,"keywords":569,"overallStatus":132,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":575,"startDateStruct":576,"completionDateStruct":578,"leadSponsor":579,"locationsCount":580},"100514467","feasibility-study-of-sentinel-navigation-surgery-in-early-gastric-cancer-using-fluorescence-senorita4-100514467","NCT05978882","Feasibility Study of Sentinel Navigation Surgery in Early Gastric Cancer Using Fluorescence (SENORITA4)","Feasibility Study of Sentinel Navigation Surgery in Early Gastric Cancer Using Fluorescence (SENORITA4 Trial)","Inclusion Criteria:\n\n* single lesion of adenocarcinoma in preoperative endoscopic biopsy clinical stage T1N0 in the preoperative evaluation of endoscopy and computed tomography\n* tumor size: less than 3cm\n* location: 2cm far from the pylorus or cardia\n* aged 20 to 80\n* ECOG 0 or 1\n* patient who signed the agreement\n* patient who is suspected to underwent laparoscopic or robotic gastrectomy\n\nExclusion Criteria:\n\n* indication of endoscopic submucosal resection\n* inoperable due to poor cardiac, and pulmonary function\n* pregnant\n* having allergic reaction, previous upper abdominal surgery except laparoscopic cholecystectomy, previous radiation therapy to upper abdomen\n* diagnosed as malignancy within 5 years except carcinoma in situ of cervix cancer and thyroid cancer",{"count":564,"type":20},203,[23],"SENORITA 1 trial showed laparoscopic sentinel lymph node biopsy and stomach preserving surgery in early gastric cancer can increase the quality of life. (Ryu KW et al. JCO 2022) The radioactive isotope is difficult to use because of the hazard of radiation and shortage of materials. The aim of this study is to investigate whether laparoscopic sentinel lymph node biopsy and stomach-preserving surgery using only fluorescence is feasible.",[568],"Early Gastric Cancer",[474,570,571,572,573],"Sentinel lymph node","Fluorescence","Stomach-preserving surgery","Quality of life","2023-07-31",{"date":549,"type":34},{"date":577,"type":20},"2023-08-17",{"date":108,"type":20},{"name":40,"class":41},7,{"id":582,"slug":583,"hasResults":11,"nctId":584,"briefTitle":585,"officialTitle":586,"acronym":4,"eligibilityCriteria":587,"healthyVolunteers":11,"sex":51,"minAge":17,"maxAge":4,"enrollmentInfo":588,"targetDuration":4,"studyType":21,"phases":590,"briefSummary":591,"conditions":592,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":595,"lastUpdatePostDateStruct":596,"startDateStruct":598,"completionDateStruct":600,"leadSponsor":601,"locationsCount":602},"100419332","survival-rates-and-quality-of-life-according-to-follow-up-period-after-gastrectomy-for-gastric-cancer-stofolup-100419332","NCT04740346","Survival Rates and Quality of Life According to Follow-up Period After Gastrectomy for Gastric Cancer (STOFOLUP)","A Prospective Multi-center Randomized Clinical Trial to Compare Survival Rates and Quality of Life According to Follow-up Period in Patients Who Underwent Radical Gastrectomy for Advanced Gastric Cancer (STOFOLUP Trial)","Inclusion Criteria:\n\n* Patients aged 19 years or more\n* Patients who are diagnosed with pathological stage II or III gastric adenocarcinoma according to the AJCC 8th edition\n* Patients who can understand all information about the trial and decide for themselves whether to participate in this study\n\nExclusion Criteria:\n\n* Vulnerable patients such as pregnant and intellectual disability\n* Patients who cannot undergo CT owing to poor kidney function or severe adverse effects\n* Patients who are already in another study and cannot follow the schedule for this trial\n* Patients who are diagnosed with a cancer other than gastric cancer within five years before the gastrectomy\n* Patients being treated for a cancer other than gastric cancer",{"count":589,"type":20},886,[23],"This study is a multi-center, prospective, randomized controlled study. The aim of this study is to compare survival rates and to observe quality of life and nutritional status according to follow-up period in patients who underwent radical gastrectomy for stage 2 or 3 gastric cancer.",[501,593,594],"Recurrence","Quality of Life","2021-10-26",{"date":597,"type":34},"2021-10-27",{"date":599,"type":34},"2021-07-05",{"date":334,"type":20},{"name":40,"class":41},16,""]